Dr. Mexal graduated with honors from the University of New Mexico with a B.S. in Biology and with a Ph.D. from the Human Medical Genetics Program at the University of Colorado Medical Campus. Dr. Mexal completed her post-doctoral research at the University of Colorado at Boulder Institute for Behavioral Genetics. Prior to joining Ambry in 2009, she worked as a senior scientist at Cenomed Biosciences, a start-up pharmaceutical company, where she screened novel compounds for anti-psychotic and anti-emetic drug activity. Dr. Mexal has been active in medical genetics research for over a decade and has published numerous articles on the genetics of schizophrenia and tobacco addiction.